I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

Jennifer E. Engen

SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinical trial (TALLER) of highly differentiated long-acting recombinant human growth hormone eftansomatropin […]

5 Best Pediatric Dentists in Oakland, CA

Jennifer E. Engen

Below is a list of the top and leading Pediatric Dentists in Oakland. To help you find the best Pediatric Dentists located near you in Oakland, we put together our own list based on this rating points list. Oakland’s Best Pediatric Dentists:  The top-rated Pediatric Dentists in Oakland, CA are: Little […]

Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency :: OPKO Health, Inc. (OPK)

Jennifer E. Engen

Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency     NEW YORK and MIAMI, February 15, 2022 – Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) […]

Get to the Roots of Pediatric Acne

Jennifer E. Engen

Health care providers asked Dermatology Times® for resources to help answer questions like these and address their young patients’ needs for fast, effective, and safe skin clearance as well as improved quality of life (QOL). In response, Dermatology Times® collaborated with 2 sister brands, Contemporary Pediatrics® and Psychiat- ric TimesTM, […]

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency

Jennifer E. Engen

NEW YORK & MIAMI–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the […]